End to end CDMO services for the importation, encapsulation and distribution of T3S and Placebo for the LIONNS-D2 Trial

Scope of works

Award notice for the above CDMO services tender. Previous description as follows - The School of Medicine successfully applied for a UKRI grant to investigate in a randomised controlled trial (RCT), a new IMP (investigational medicinal product) called Triiodothyronine sulphate (T3S) in hypothyroid subjects with a gene difference in a thyroid related enzyme called deiodinase 2 (D2). We are looking for a CDMO to (i) Import and QP sign off T3S and matched placebo tablets obtained from Ardena, Pamplona, Spain who will manufacture these to GMP standards; (ii) over encapsulate commercially secured L-thyroxine (LT4 ) and matched placebo capsules; (iii) store T3S and matched placebo obtained from Ardena, and over encapsulated LT4 and matched placebo; (iv) label T3S, LT4 and respective placebo packs for distribution to trial subjects; (v) distribute T3S and matched placebo and over encapsulated LT4 and matched placebo packs to trial pharmacy (Royal Glamorgan Hospital, Wales).

Type

Contract award

Contract Award

Sector

Pharmaceuticals & Life Sciences

Procedure

Competitive flexible procedure

Classification

Not published at source

Original notice

Sign in to open the original notice

Source provenance (1)

Every portal notice that contributed to this record, with the values each one published. Where portals disagree, the originating notice is the published record.

Key dates

1. Published at source18 Sept 2026
2. Submission deadline—